Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Cigdem Erten"'
Autor:
Suna Cokmert, Lutfiye Demir, Aysegul Akder Sari, Yuksel Kucukzeybek, Alper Can, Murat Akyol, Ibrahim Vedat Bayoglu, Ahmet Dirican, Cigdem Erten, Mustafa Oktay Tarhan
Publikováno v:
Case Reports in Oncological Medicine, Vol 2013 (2013)
Externí odkaz:
https://doaj.org/article/ba7799750fb3446b9241dc5075796105
Autor:
Ahmet Alacacioglu, Sengul Varol, S. Leyla Aslan, Isil Somali, Ugur Muslu, Cigdem Erten, M. Oktay Tarhan
Publikováno v:
Breast care (Basel, Switzerland). 4(5)
The aim of the present study was to investigate the use of complementary and alternative medicine (CAM) and the factors that influence their use in patients with breast cancer.This descriptive and cross-sectional study was carried out with 135 breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ca59e35f2ef9f2520b1b474add6311f
https://pubmed.ncbi.nlm.nih.gov/30397401
https://pubmed.ncbi.nlm.nih.gov/30397401
Publikováno v:
Clinical and Translational Oncology. 17:145-151
The treatment of castrate-resistant prostate cancer (CRPC) still remains as an important challenge of daily oncology practice. Docetaxel significantly prolongs overall survival in men with CRPC. Thymoquinone (TQ), one of the flavonoid compounds isola
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1c3ad9f0c22c5ced7b9a2b24f6f144
https://doi.org/10.1007/s12094-014-1206-6
https://doi.org/10.1007/s12094-014-1206-6
Autor:
Suna Timur, Furkan Ulus, Cigdem Erten, F. Nil Ertaş, K. Volkan Özdokur, İrem Aydın, Levent Pelit, Dilek Odaci Demirkol, Elvin Yavuz, Bilal Demir
Publikováno v:
Sensors and Actuators B: Chemical. 197:123-128
Present study reports the use of a glassy carbon electrode modified with manganese oxide decorated with platinum nanoparticles (Pt-MnOx/GCE) for electrocatalytic reduction of oxygen dissolved in buffer solution. The electrode exhibits better electroc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be81c7678622bd142f1c64df605e3cb
https://doi.org/10.1016/j.snb.2014.01.122
https://doi.org/10.1016/j.snb.2014.01.122
Autor:
Mustafa Oktay Tarhan, Eyup Coban, Umut Varol, Ahmet Alacacioglu, Alper Can, Murat Akyol, Ahmet Dirican, Isil Somali, Ibrahim Vedat Bayoglu, Betul Koyuncu, Yuksel Kucukzeybek, Lutfiye Demir, Yasar Yildiz, Cigdem Erten
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 15:4781-4786
Background: The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab. Materials and Methods: A total of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da0a03b514eb8ab0f14d88d8b61ca50a
https://doi.org/10.7314/apjcp.2014.15.12.4781
https://doi.org/10.7314/apjcp.2014.15.12.4781
Autor:
Ibrahim Vedat Bayoglu, Umut Varol, Mustafa Oktay Tarhan, Yasar Yildiz, Ahmet Alacacioglu, Betul Koyuncu, Fulya Cakalagaoglu Unay, Betul Bolat Kucukzeybek, Ahmet Dirican, Cigdem Erten, Yuksel Kucukzeybek, Lutfiye Demir, Isil Somali, Eda Ulger, Eyup Coban, Murat Akyol
Publikováno v:
International Journal of Clinical Oncology. 20:70-81
The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with cancer. Similarly, a study in a large series has shown that the newly defined derived NLR (dNLR; neutrophil/leukocyte–lymphocyte ratio) also has prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9322f0ad2920751d0dba361a524fb976
https://doi.org/10.1007/s10147-014-0672-8
https://doi.org/10.1007/s10147-014-0672-8
Autor:
Mustafa Oktay Tarhan, Lutfiye Demir, Ahmet Alacacioglu, Yuksel Kucukzeybek, Cigdem Erten, Alper Can, Ahmet Dirican, Isil Somali, Vedat Bayoglu, Murat Akyol, Suna Cokmert, Nese Ekinci
Publikováno v:
Journal of Surgical Oncology. 109:665-675
Background and Objectives We aimed to evaluate the prognostic value of cell cycle proteins and p53 together with clinicopathologic features in non-metastatic resected colon cancer. Methods One hundred nine patients who were diagnosed with resected co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05106d421af51dadb7a43efef35aee9d
https://doi.org/10.1002/jso.23563
https://doi.org/10.1002/jso.23563
Autor:
Ahmet Alacacioglu, Isil Somali, Seyran Yigit, Cigdem Erten, Hülya Ellidokuz, Lutfiye Demir, Mustafa Oktay Tarhan, Bahar Yakut Ustaoglu
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 14:6013-6017
Background: To evaluate the clinicopathologic and demographic characteristics of triple-negative breast cancer (TNBC) patients and to determine differences from non-triple-negative cases. Materials and Methods: A detailed review of the medical record
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba15ce52b83dda88c8e4c44975c3baa7
https://doi.org/10.7314/apjcp.2013.14.10.6013
https://doi.org/10.7314/apjcp.2013.14.10.6013
Autor:
Mustafa Oktay Tarhan, Betul Koyuncu, Arzu Avci, Alper Can, Isil Somali, Ahmet Dirican, Lutfiye Demir, Eda Ulger, Yuksel Kucukzeybek, Ahmet Alacacioglu, Nese Ekinci, Cigdem Erten, Murat Akyol, Ibrahim Vedat Bayoglu
Publikováno v:
Cancer Biomarkers. 13:11-20
BACKGROUND: It is well known that tumor-infiltrating lymphocytes (TIL) and, to a lesser extent, peripheral hematologic parameters from patients with cancer have to effect on prognosis. The aim of this study was to evaluate the effect of hematologic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5dee44f9b7b6c2d29881eeddc97f88
https://doi.org/10.3233/cbm-130331
https://doi.org/10.3233/cbm-130331
Autor:
Murat Akyol, Ahmet Alacacioglu, Ahmet Dirican, Mehmet Koseoglu, Alper Can, Yuksel Kucukzeybek, Mustafa Oktay Tarhan, Lutfiye Demir, Yasar Yildiz, Isil Somali, Ibrahim Vedat Bayoglu, Kadriye Bahriye Payzin, Cigdem Erten
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 14:2101-2105
Background: Long-term survival is a problem with locally advanced and metastatic renal cell carcinomas. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, but data on sunitinib use as a second line treatment in metastatic renal cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12ab93bbb850fd28f59b450c0166681
https://doi.org/10.7314/apjcp.2013.14.3.2101
https://doi.org/10.7314/apjcp.2013.14.3.2101